铁喹对柬埔寨ACT耐药恶性疟原虫分离株的体外活性
该研究在柬埔寨对80株恶性疟原虫分离株进行体外药敏测试,分析铁喹对ACT耐药相关分子特征虫株的活性。结果显示总体中位IC50为10.9 nM,Pfk13 C580Y伴Pfpm2扩增株的IC50最高(17.2 nM),但仍在无ACT耐药地区范围内,提示铁喹对ACT耐药疟疾有潜在疗效。
要点
- 铁喹对柬埔寨ACT耐药恶性疟原虫分离株总体中位IC50为10.9 nM。
- Pfk13 C580Y伴Pfpm2扩增株对铁喹耐受性最高,中位IC50为17.2 nM。
- 铁喹敏感性范围与无ACT耐药地区一致,值得作为ACT耐药疟疾的治疗选择。
核心结论
- 铁喹对ACT耐药分离株表现出有前景的疗效。
- Pfpm2扩增与对铁喹的最高耐受性相关,但观察到的敏感性范围与无ACT耐药地区一致。
- 铁喹可考虑作为ACT耐药疟疾的相关治疗选择。
研究设计与样本
- 研究对来自柬埔寨的80株恶性疟原虫分离株进行体外铁喹药敏测试。
- 所有分离株均表征了其对青蒿素、哌喹和甲氟喹的分子耐药谱。
主要发现
- 80株分离株中铁喹总体中位(IQR)IC50为10.9 nM(8.7-18.3)。
- Pfk13野生型虫株铁喹中位(IQR)IC50为8.9 nM(8.1-11.8),Pfk13 C580Y且Pfpm2和Pfmdr1未扩增株为12.9 nM(9.5-20.0)。
- Pfk13 C580Y伴Pfpm2扩增株铁喹中位(IQR)IC50为17.2 nM(14.5-20.5),伴Pfmdr1扩增株为9.1 nM(7.9-10.7)。
关键数值与推荐
- 铁喹对ACT耐药分离株的体外活性以IC50评估,总体中位值为10.9 nM。
- Pfk13 C580Y伴Pfpm2扩增株的铁喹IC50最高,中位值为17.2 nM。
临床怎么用
- 铁喹对ACT耐药恶性疟原虫分离株的体外活性支持其作为潜在治疗选择进一步研究。
- 对Pfk13 C580Y伴Pfpm2扩增的虫株需关注铁喹敏感性降低的可能。
局限性
- 研究仅为体外药敏测试,未提供临床疗效或体内数据。
- 样本仅来自柬埔寨80株分离株,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cambodia is the epicentre of resistance emergence for virtually all antimalarial drugs. Selection and spread of parasites resistant to artemisinin-based combination therapy (ACT) is a major threat for malaria elimination, hence the need to renew the pool of effective treatments. OBJECTIVES: To determine whether ACT resistance haplotypes could have an effect on ferroquine in vitro antimalarial activity. METHODS: In vitro susceptibility to ferroquine was measured for 80 isolates from Cambodia characterized for their molecular resistance profile to artemisinin, piperaquine and mefloquine. RESULTS: Among the 80 isolates tested, the overall median (IQR) IC50 of ferroquine was 10.9 nM (8.7-18.3). The ferroquine median (IQR) IC50 was 8.9 nM (8.1-11.8) for Pfk13 WT parasites and was 12.9 nM (9.5-20.0) for Pfk13 C580Y parasites with no amplification of Pfpm2 and Pfmdr1 genes. The median (IQR) IC50 of ferroquine for Pfk13 C580Y parasites with amplification of the Pfpm2 gene was 17.2 nM (14.5-20.5) versus 9.1 nM (7.9-10.7) for Pfk13 C580Y parasites with amplification of the Pfmdr1 gene. CONCLUSIONS: Ferroquine exerts promising efficacy against ACT-resistant isolates. Whereas Pfpm2 amplification was associated with the highest parasite tolerance to ferroquine, the susceptibility range observed was in accordance with those measured in ACT resistance-free areas. This enables consideration of ferroquine as a relevant therapeutic option against ACT-resistant malaria.
引用
- Mairet-Khedim M, Nardella F, Khim N, et al. In vitro activity of ferroquine against artemisinin-based combination therapy (ACT)-resistant Plasmodium falciparum isolates from Cambodia. J Antimicrob Chemother. 2019. PMID: 31518407. doi:10.1093/jac/dkz340
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。